Answers are grounded in this paper and cite their sources.
This study aimed to identify potential allosteric inhibitors targeting the epidermal growth factor receptor (EGFR) with the triple resistance mutations L858R, T790M, and L718Q through an integrated pharmacophore-guided virtual screening approach. Pharmacophore models were constructed based on the allosteric inhibitors EAI001 and EAI045, and their performance was evaluated using sensitivity and specificity parameters. The best-performing model (Model 4; sensitivity = 1, specificity = 0.92) was employed to screen the NCI Open Chemical Repository Database. Docking analyses were conducted against both the template and mutant EGFR structures using the Affinity dG scoring function with Alpha PMI placement. Toxicological profiles were predicted, and the stability of the selected complexes was assessed through 100 ns molecular dynamics simulations. Virtual screening identified 1,628 candidate compounds, and subsequent docking revealed 14 molecules with stronger binding affinities than the reference ligand. Among these, compound NSC3 demonstrated the highest affinity for both the template and mutant EGFR. Toxicological predictions indicated possible carcinogenicity, hepatotoxicity, and mutagenicity for some candidates. Molecular dynamics analyses showed that NSC3 exhibited greater conformational stability and hydrogen-bond persistence than EAI001. EAI001 displayed limited activity against the L718Q mutation, whereas NSC3 emerged as a promising allosteric inhibitor candidate for EGFR triple resistance mutations. These findings provide a rational foundation for further experimental validation and optimization in the development of next-generation EGFR inhibitors.
No takes yet. Share an insight, caveat, or question.
Ramadhan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: